IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytes
Open Access
- 24 March 2021
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 64 (7) , 1690-1702
Abstract
Aims/hypothesis: Podocyte loss or injury is one of the earliest features observed in the pathogenesis of diabetic kidney disease (DKD), which is the leading cause of end-stage renal failure worldwide. Dysfunction in the IGF axis, including in IGF binding proteins (IGFBPs), is associated with DKD, particularly in the early stages of disease progression. The aim of this study was to investigate the potential roles of IGFBPs in the development of type 2 DKD, focusing on podocytes. Methods: IGFBP expression was analysed in the Pima DKD cohort, alongside data from the Nephroseq database, and in ex vivo human glomeruli. Conditionally immortalised human podocytes and glomerular endothelial cells were studied in vitro, where IGFBP-1 expression was analysed using quantitative PCR and ELISAs. Cell responses to IGFBPs were investigated using migration, cell survival and adhesion assays; electrical cell-substrate impedance sensing; western blotting; and high-content automated imaging. Results: Data from the Pima DKD cohort and from the Nephroseq database demonstrated a significant reduction in glomerular IGFBP-1 in the early stages of human type 2 DKD. In the glomerulus, IGFBP-1 was predominantly expressed in podocytes and controlled by phosphoinositide 3-kinase (PI3K)–forkhead box O1 (FoxO1) activity. In vitro, IGFBP-1 signalled to podocytes via β1-integrins, resulting in increased phosphorylation of focal-adhesion kinase (FAK), increasing podocyte motility, adhesion, electrical resistance across the adhesive cell layer and cell viability. Conclusions/interpretation: This work identifies a novel role for IGFBP-1 in the regulation of podocyte function and that the glomerular expression of IGFBP-1 is reduced in the early stages of type 2 DKD, via reduced FoxO1 activity. Thus, we hypothesise that strategies to maintain glomerular IGFBP-1 levels may be beneficial in maintaining podocyte function early in DKD. GraphicalKeywords
Funding Information
- Horizon2020-IMI Biomarker Enterprise to Attack Diabetic Kidney Disease
- Kidney Research UK (S/RP/2015/4)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK081943)
- Society for Endocrinology
- Medical Research Council (MR/K010492/1)
This publication has 61 references indexed in Scilit:
- Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplayEMBO Molecular Medicine, 2013
- Increasing Circulating IGFBP1 Levels Improves Insulin Sensitivity, Promotes Nitric Oxide Production, Lowers Blood Pressure, and Protects Against AtherosclerosisDiabetes, 2012
- Transcriptome Analysis of Human Diabetic Kidney DiseaseDiabetes, 2011
- Systematic Analysis of a Novel Human Renal Glomerulus-Enriched Gene Expression DatasetPLOS ONE, 2010
- Inhibition of Podocyte FAK Protects against Proteinuria and Foot Process EffacementJournal of the American Society of Nephrology, 2010
- Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysisThe Lancet, 2010
- mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytesAmerican Journal of Physiology-Renal Physiology, 2009
- β1 integrin expression by podocytes is required to maintain glomerular structural integrityDevelopmental Biology, 2008
- Novel roles of the IGF–IGFBP axis in etiopathophysiology of diabetic nephropathyDiabetes Research and Clinical Practice, 2007
- Focal adhesion kinase: in command and control of cell motilityNature Reviews Molecular Cell Biology, 2005